Drug giant profits millions from Russian sales

A subsidiary of a major pharmaceutical company has achieved significant financial success through its operations in Russia, accumulating a profit of hundreds of millions. The company's Danish subsidiary, in particular, has reported a three-digit million surplus from its sales of medicine within the Russian market.

This substantial profit generation comes at a time when many international companies have withdrawn from Russia following its invasion of Ukraine. The continued business activities and subsequent financial gains are expected to draw criticism from various quarters.

An expert in the field anticipates that the pharmaceutical giant will face scrutiny and potential backlash for its ongoing commercial engagement in Russia. The financial success of the subsidiary highlights the complex ethical and economic considerations faced by multinational corporations operating in the current geopolitical climate.